{
  "uuid": "b6346a08-4fa0-4022-b597-6c4078fb15a6",
  "created_at": "2025-11-22 19:58:59",
  "raw_json": {
    "article_author": null,
    "article_headline": null,
    "article_modified": null,
    "article_published": null,
    "article_section": null,
    "article_tags": null,
    "canonical_url": "https://www.r-bloggers.com/2025/03/fda-compliance-in-software-development-cases-where-poor-software-quality-led-to-costly-fda-rejections/",
    "crawled_at": "2025-11-22T10:51:44.872662",
    "external_links": [
      {
        "href": "https://appsilon.com/pharma-fda-rejections/",
        "text": "Appsilon | Enterprise R Shiny Dashboards"
      },
      {
        "href": "http://r-posts.com/",
        "text": "here"
      },
      {
        "href": "https://www.appsilon.com/services/gxp-software-engineering",
        "text": "GxP compliance in software development"
      },
      {
        "href": "https://www.appsilon.com/post/gxp-software-validation-starts-with-definition-of-done",
        "text": "Read how Appsilon implements it for Fortune 500 companies"
      },
      {
        "href": "https://www.investopedia.com/applied-therapeutics-stock-plummets-after-fda-rejects-metabolic-disease-drug-8753289",
        "text": "Applied Therapeutics (APLT) stock plummeted"
      },
      {
        "href": "https://finance.yahoo.com/quote/APLT/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAAjLl2bjREMq0Uai118W_Fs1rk1JbJh_pwxdUtSl7xFjT_gHu-eYQ8m7Za5tmxr3nL0wbc2n5-WK6bv1ONdnkWkpBkMT4Iy6_0tsCaoMbDZ-VxYh1Xu1tXgkVuSOa2XFPy0dzFhWou1Fn-NzSI0tBjLMfpiNNw4IysJLikfi2Cri",
        "text": "Yahoo Finance"
      },
      {
        "href": "https://www.proactiveinvestors.com/companies/news/1024946/outlook-therapeutics-collapses-as-fda-rejects-application-for-eye-drug-1024946.html",
        "text": "Outlook Therapeutics collapses as FDA rejects application for eye drug"
      },
      {
        "href": "https://www.fiercepharma.com/manufacturing/fda-rejects-theratechnologies-drug-application-problems-largely-centered",
        "text": "FDA rejects Theratechnologies application, with problems ‘largely’ centered on manufacturing"
      },
      {
        "href": "https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation",
        "text": "2023 FDA Warning Letters and Software Validation"
      },
      {
        "href": "https://www.fda.gov/",
        "text": "FDA"
      },
      {
        "href": "https://www.appsilon.com/post/gxp-audit-software",
        "text": "‍"
      },
      {
        "href": "https://www.appsilon.com/post/gxp-audit-software",
        "text": "Learn more about how our GxP Audit Service can help you navigate FDA and EMA submissions"
      },
      {
        "href": "https://www.appsilon.com/guides/gxp-compliance",
        "text": "comprehensive guide on navigating GxP compliance"
      },
      {
        "href": "https://www.appsilon.com/resources/definition-of-done-checklist-for-pharma-teams",
        "text": "Definition of Done (DoD) Checklist for Pharma Teams"
      },
      {
        "href": "https://www.appsilon.com/contact-us",
        "text": "reach out to Appsilon"
      },
      {
        "href": "https://appsilon.com/pharma-fda-rejections/",
        "text": "Appsilon | Enterprise R Shiny Dashboards"
      },
      {
        "href": "https://feedburner.google.com/fb/a/mailverify?uri=RBloggers",
        "text": "daily e-mail updates"
      },
      {
        "href": "https://www.r-project.org/",
        "text": "R"
      },
      {
        "href": "https://www.r-users.com/",
        "text": "Click here if you're looking to post or find an R/data-science job"
      },
      {
        "href": "http://r-posts.com/",
        "text": "here"
      }
    ],
    "h1_title": "R-bloggers",
    "html_title": "FDA Compliance in Software Development: Cases Where Poor Software Quality Led to Costly FDA Rejections | R-bloggers",
    "images": [
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://wordpress.appsilon.com/wp-content/uploads/2025/03/67cb14f56eab8476242d0af9_66fc17578edc39e2a907790a_Rounding_4-p-1600.webp"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f8993c6798fa7016_AD_4nXeGVW_EJnKufaSkgmIlj1bjlMEGutXro7tl81GQJzspDLiyrOWC389REVOWWQIBAIsnQl0iTExaUzKv4Fcs6nCurMGnSH4iNNRawu3ItifHpNbkAKoW0z5OT33z3vQVciIBYVTqFA.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i1.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f45042a3aee46be3_AD_4nXcqzChQ2fzFzKt8ACKC0I6A79x6C5n3msdj6IMH1i9OfUyspnHyqI_IiZLGwBQISVzTYu4u_HZcSe8lerSWlX-wRk7u8Ea7JZP1Qa06IF_1bthGx5bpda4bTw9VPywREg3iqYxR.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319d54a4a3f8280e648_AD_4nXcuTgHhp_X5npO7TtkWMWqbHqA-4JDXd8CUOoLhDNkp9bfy7zIZEDj_BT2Svamar2Tqn7FTeqvDLQ3XgsrH42h5AmY6cK-TYxTgHzQaAudnNqiu2TIOujpq9nG8Wgo_fwp7DnFl.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319114b66b4a9786bb9_AD_4nXcWNPsp3QR1ma6evuAgU6iNkgir80qnvpdQCWeRCzI8uvs-6hS0wiSAJilI_BNXv6r2kHiarmUBjCVtXv5qTfVqM3sx8r6GgYYBdoe47d7vM3gI85lIFKNfGXTNS1nfnMJ0O2Vx.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319802a7f2bdc92e26e_AD_4nXf5fGQBVbyvPH8X1uQaDUMN6dg4q0LFqdAdqajRE4CfGEchpx3CCe9h0CoWkjfJ4X1IKVoqpOuMd174A6x2RK_jvw1KcpDP34i7vd_zbHpdOgXEX2TU4xPw8TQu-dRS9g9Muph-.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i1.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319d57aaf27bf3ab849_AD_4nXfcweb0IWHdjXcdV6QShRUjUgesIncIoK0GBOPiz0YEfoQt_9w9Sz4E-GAaJRilCPUd_lCiiZ8jhYkSc3m-Hm6R8hBNtLaJZSNuB0q3e0xQqPyM0KBn79DSvqPiGnhtRcbM69EkfQ.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i2.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f692e0cb3df98ca1_AD_4nXcrER19TaxT-aneFQEZBY4gM7_IyHZXcpZeCyhzqNT1Iy0nTM0YpOM3sak1BX2bFTjJotcxIL_TR3RVlwK_zGgKNPslGy7FOQiBL4ATIGKLtCqeUfR3vAvTLT4MbhukqKYlhP0.png?w=578&ssl=1"
      },
      {
        "alt": null,
        "base64": "data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7",
        "src": "https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif"
      },
      {
        "alt": null,
        "base64": null,
        "src": "https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb13187fdbc66e3fc7c294_AD_4nXe1ErWEF2_ONjE2xsynUqkNC6_I-7U0sG-urdv_gHFenn6hOaTUsmg5QZJdkuTV8cB0F7aDK-RbNN8sie_Ak9Yscwt16OSnSHZhjOgle9wUoQHqQZomdpEDMl2vHHMlaj5wWnHJ.png?w=578&ssl=1"
      }
    ],
    "internal_links": [
      {
        "href": "https://www.r-bloggers.com/author/pawel-przytula/",
        "text": "Paweł Przytuła"
      },
      {
        "href": "https://www.r-bloggers.com/category/r-bloggers/",
        "text": "R bloggers"
      },
      {
        "href": "https://www.r-bloggers.com/",
        "text": "R-bloggers"
      },
      {
        "href": "https://www.r-bloggers.com/contact-us/",
        "text": "here"
      },
      {
        "href": "https://www.r-bloggers.com/add-your-blog/",
        "text": "click here"
      },
      {
        "href": "https://www.r-bloggers.com/",
        "text": "R-bloggers.com"
      },
      {
        "href": "https://www.r-bloggers.com/how-to-learn-r-2/",
        "text": "learning R"
      },
      {
        "href": "https://www.r-bloggers.com/add-your-blog/",
        "text": "click here"
      }
    ],
    "lang": "en-US",
    "main_html": "<article class=\"post-391448 post type-post status-publish format-standard hentry category-r-bloggers\">\n<header class=\"post-header\">\n<h1 class=\"entry-title\">FDA Compliance in Software Development: Cases Where Poor Software Quality Led to Costly FDA Rejections</h1>\n<p class=\"meta post-meta\">Posted on <span class=\"updated\">March 25, 2025</span>  by <span class=\"vcard author\"><a class=\"fn\" href=\"https://www.r-bloggers.com/author/pawel-przytula/\">Paweł Przytuła</a></span>  in <a href=\"https://www.r-bloggers.com/category/r-bloggers/\" rel=\"category tag\">R bloggers</a> | 0 Comments</p>\n</header>\n<div class=\"entry clearfix\">\n<!-- \n<div style=\"min-height: 30px;\">\n[social4i size=\"small\" align=\"align-left\"]\n</div>\n-->\n<div style=\"border: 1px solid; background: none repeat scroll 0 0 #EDEDED; margin: 1px; font-size: 12px;\">\n[This article was first published on  <strong><a href=\"https://appsilon.com/pharma-fda-rejections/\"> Appsilon | Enterprise R Shiny Dashboards</a></strong>, and kindly contributed to <a href=\"https://www.r-bloggers.com/\" rel=\"nofollow\">R-bloggers</a>].  (You can report issue about the content on this page <a href=\"https://www.r-bloggers.com/contact-us/\">here</a>)\n<hr/>Want to share your content on R-bloggers?<a href=\"https://www.r-bloggers.com/add-your-blog/\" rel=\"nofollow\"> click here</a> if you have a blog, or <a href=\"http://r-posts.com/\" rel=\"nofollow\"> here</a> if you don't.\n</div>\n\n<!-- Share buttons by mashshare.net - Version: 4.0.47--><div><img alt=\"\" class=\"attachment-medium size-medium wp-post-image\" data-lazy-src=\"https://wordpress.appsilon.com/wp-content/uploads/2025/03/67cb14f56eab8476242d0af9_66fc17578edc39e2a907790a_Rounding_4-p-1600.webp\" decoding=\"async\" loading=\"lazy\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\" style=\"margin-bottom: 15px;\" width=\"450\"/><noscript><img alt=\"\" class=\"attachment-medium size-medium wp-post-image\" decoding=\"async\" loading=\"lazy\" src=\"https://wordpress.appsilon.com/wp-content/uploads/2025/03/67cb14f56eab8476242d0af9_66fc17578edc39e2a907790a_Rounding_4-p-1600.webp\" style=\"margin-bottom: 15px;\" width=\"450\"/></noscript></div><p>If you work in pharma, you know how much time and money go into drug development. The last thing you want is a painful FDA rejection, one that not only costs your company millions but also delays critical treatments for patients who need them.</p>\n<p>Regulatory rejections can happen for many reasons, such as insufficient clinical evidence, manufacturing and quality concerns, incomplete applications or missing data, and general safety issues. However, in recent years, <strong>poor software quality</strong> has become a growing yet often overlooked factor.</p>\n<p>By “software,” we mean not just applications, but also programming environments, languages, and the tools used to process and govern clinical data. As more pharmaceutical companies explore open-source technologies like R alongside SAS for clinical trial analysis, regulatory bodies are paying closer attention to software quality and compliance.</p>\n<p>With that in mind, <a href=\"https://www.appsilon.com/services/gxp-software-engineering\" rel=\"nofollow\" target=\"_blank\">GxP compliance in software development</a> is critical to making this transition smooth and secure. In this article, we’ll examine cases where software quality issues led to costly FDA rejections—so you can learn what to watch for and how to avoid similar setbacks.</p>\n<blockquote><p><em>GxP validation in software development starts with the Definition of Done. </em><a href=\"https://www.appsilon.com/post/gxp-software-validation-starts-with-definition-of-done\" rel=\"nofollow\" target=\"_blank\"><em>Read how Appsilon implements it for Fortune 500 companies</em></a><em>.</em></p></blockquote>\n<h3>Table of contents</h3>\n<ul role=\"list\">\n<li>Are Software Quality Issues a Common Reason for FDA Rejections?</li>\n<li>How FDA Rejection Can Cost Your Company Three-Quarters of its Valuation – And How to Avoid It</li>\n<li>Appsilon’s Role in GxP Compliance</li>\n</ul>\n<h2><strong>Are Software Quality Issues a Common Reason for FDA Rejections?</strong></h2>\n<p>There are many reasons why the FDA might reject your drug submission or request improvements during an inspection.</p>\n<p>While issues like insufficient clinical evidence, manufacturing concerns, and missing data are often the most cited reasons, software quality plays a crucial role in ensuring compliance and data integrity.</p>\n<p>For example, poor data processing or flawed statistical analyses can lead to <strong>insufficient clinical evidence</strong>, where trial results fail to demonstrate efficacy due to errors in data handling. Similarly, compliance issues in <strong>manufacturing and quality control</strong> may arise if software systems used for tracking and reporting do not meet regulatory expectations.</p>\n<p>The following reasons are much more common:</p>\n<ul role=\"list\">\n<li><strong>Insufficient clinical evidence:</strong> Lack of sufficient data demonstrating the drug’s efficacy.</li>\n<li><strong>Manufacturing and quality concerns:</strong> Non-compliance with <em>Current Good Manufacturing Practices</em> (CGMP), which ensure consistency and safety in drug production.</li>\n<li><strong>Incomplete applications or missing data:</strong> Gaps in documentation or failure to provide required study results.</li>\n<li><strong>Safety concerns:</strong> Adverse effects of the drug that outweigh its potential benefits.</li>\n</ul>\n<p>However, this doesn’t mean that the FDA doesn’t pay attention to software quality.</p>\n<p>The FDA and other regulatory bodies closely examine the tools and methodologies used in data analysis, clinical trial reporting, and regulatory submissions.  They also receive the data needed to reproduce the analyses done by the sponsor.</p>\n<p>If your company uses programming languages like R or Python for these tasks, the FDA may evaluate whether your scripts and validation processes comply with their expectations.</p>\n<h2><strong>How an FDA Rejection Can Cost Your Company Three-Quarters of Its Valuation – And How to Avoid It</strong></h2>\n<p>Let’s start with a devastating FDA rejection case that broke one company overnight.</p>\n<p>In late November 2024, <a href=\"https://www.investopedia.com/applied-therapeutics-stock-plummets-after-fda-rejects-metabolic-disease-drug-8753289\" rel=\"nofollow\" target=\"_blank\">Applied Therapeutics (APLT) stock plummeted</a> after the FDA rejected its metabolic disease drug. And when we say “plummeted,” we mean it – <strong>APLT lost three-quarters of its valuation almost instantly</strong>:</p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f8993c6798fa7016_AD_4nXeGVW_EJnKufaSkgmIlj1bjlMEGutXro7tl81GQJzspDLiyrOWC389REVOWWQIBAIsnQl0iTExaUzKv4Fcs6nCurMGnSH4iNNRawu3ItifHpNbkAKoW0z5OT33z3vQVciIBYVTqFA.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f8993c6798fa7016_AD_4nXeGVW_EJnKufaSkgmIlj1bjlMEGutXro7tl81GQJzspDLiyrOWC389REVOWWQIBAIsnQl0iTExaUzKv4Fcs6nCurMGnSH4iNNRawu3ItifHpNbkAKoW0z5OT33z3vQVciIBYVTqFA.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 1 – APLT stock price (source: </em><a href=\"https://finance.yahoo.com/quote/APLT/?guccounter=1&amp;guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&amp;guce_referrer_sig=AQAAAAjLl2bjREMq0Uai118W_Fs1rk1JbJh_pwxdUtSl7xFjT_gHu-eYQ8m7Za5tmxr3nL0wbc2n5-WK6bv1ONdnkWkpBkMT4Iy6_0tsCaoMbDZ-VxYh1Xu1tXgkVuSOa2XFPy0dzFhWou1Fn-NzSI0tBjLMfpiNNw4IysJLikfi2Cri\" rel=\"nofollow\" target=\"_blank\"><em>Yahoo Finance</em></a><em>)</em></figcaption></figure>\n<p>The stock dropped from a closing price of $10.21 on November 26 to $2.03 on November 29, representing <strong>an 80% decrease</strong>.</p>\n<p>It is now February 2025, and judging by the chart, the company has yet to recover – partly due to avoidable deficiencies in its clinical application.</p>\n<p>Unfortunately, this is not the only software-related FDA rejection. Here are a few more cases that highlight the importance of GSEP (Good Software Engineering Practices):</p>\n<ul role=\"list\">\n<li><a href=\"https://www.proactiveinvestors.com/companies/news/1024946/outlook-therapeutics-collapses-as-fda-rejects-application-for-eye-drug-1024946.html\" rel=\"nofollow\" target=\"_blank\">Outlook Therapeutics collapses as FDA rejects application for eye drug</a></li>\n<li><a href=\"https://www.fiercepharma.com/manufacturing/fda-rejects-theratechnologies-drug-application-problems-largely-centered\" rel=\"nofollow\" target=\"_blank\">FDA rejects Theratechnologies application, with problems ‘largely’ centered on manufacturing</a></li>\n<li><a href=\"https://www.ketryx.com/blog/2023-fda-warning-letters-and-software-validation\" rel=\"nofollow\" target=\"_blank\">2023 FDA Warning Letters and Software Validation</a></li>\n</ul>\n<h3>Types of FDA inspections</h3>\n<p>If you’re part of a highly regulated industry like pharma, you’re probably accustomed to FDA inspections. If not, here are a few reasons why the FDA might conduct an inspection:</p>\n<ul role=\"list\">\n<li><strong>Pre-approval inspections:</strong> Conducted before approving a new drug application to verify submitted data, assess manufacturing processes, and confirm compliance.</li>\n<li><strong>Routine GMP inspections:</strong> Conducted periodically based on risk factors, typically every 2 to 4 years.</li>\n<li><strong>For-cause inspections:</strong> Triggered by complaints, adverse events, product recalls, or whistleblower reports.</li>\n<li><strong>Follow-up inspections:</strong> Conducted after a previous inspection identified significant deficiencies.</li>\n<li><strong>Bioresearch Monitoring (BIMO) inspections:</strong> Conducted to inspect clinical trials, bioequivalence studies, and laboratory practices.</li>\n<li><strong>Post-market inspections:</strong> Conducted after a product is on the market to ensure ongoing quality and regulatory compliance.</li>\n<li><strong>Foreign inspections:</strong> Conducted at overseas facilities that manufacture products for the U.S. market.</li>\n</ul>\n<h3>Examples of software-related compliance issues</h3>\n<p>Now that you know the types of inspections the FDA can conduct, let’s examine real-world FDA inspection reports that highlight software-related issues. All of these reports are publicly available on the <a href=\"https://www.fda.gov/\" rel=\"nofollow\" target=\"_blank\">FDA</a> website.</p>\n<p>Common FDA concerns related to software include software bugs, missing audit trails, security flaws, lack of backup processes, and poor validation of software systems.</p>\n<p><strong>Software bugs found, and the system for data acquisition is not properly validated:</strong></p>\n<figure class=\"w-richtext-align-center w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i1.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f45042a3aee46be3_AD_4nXcqzChQ2fzFzKt8ACKC0I6A79x6C5n3msdj6IMH1i9OfUyspnHyqI_IiZLGwBQISVzTYu4u_HZcSe8lerSWlX-wRk7u8Ea7JZP1Qa06IF_1bthGx5bpda4bTw9VPywREg3iqYxR.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i1.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f45042a3aee46be3_AD_4nXcqzChQ2fzFzKt8ACKC0I6A79x6C5n3msdj6IMH1i9OfUyspnHyqI_IiZLGwBQISVzTYu4u_HZcSe8lerSWlX-wRk7u8Ea7JZP1Qa06IF_1bthGx5bpda4bTw9VPywREg3iqYxR.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 2 – FDA inspection report (example 1)</em></figcaption></figure>\n<p>‍<strong>Lack of software security controls, no backups, and missing audit trails:</strong></p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319d54a4a3f8280e648_AD_4nXcuTgHhp_X5npO7TtkWMWqbHqA-4JDXd8CUOoLhDNkp9bfy7zIZEDj_BT2Svamar2Tqn7FTeqvDLQ3XgsrH42h5AmY6cK-TYxTgHzQaAudnNqiu2TIOujpq9nG8Wgo_fwp7DnFl.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319d54a4a3f8280e648_AD_4nXcuTgHhp_X5npO7TtkWMWqbHqA-4JDXd8CUOoLhDNkp9bfy7zIZEDj_BT2Svamar2Tqn7FTeqvDLQ3XgsrH42h5AmY6cK-TYxTgHzQaAudnNqiu2TIOujpq9nG8Wgo_fwp7DnFl.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 3 – FDA inspection report (example 2)</em></figcaption></figure>\n<p>‍<strong>No data validation procedures and no access controls:</strong></p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319114b66b4a9786bb9_AD_4nXcWNPsp3QR1ma6evuAgU6iNkgir80qnvpdQCWeRCzI8uvs-6hS0wiSAJilI_BNXv6r2kHiarmUBjCVtXv5qTfVqM3sx8r6GgYYBdoe47d7vM3gI85lIFKNfGXTNS1nfnMJ0O2Vx.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319114b66b4a9786bb9_AD_4nXcWNPsp3QR1ma6evuAgU6iNkgir80qnvpdQCWeRCzI8uvs-6hS0wiSAJilI_BNXv6r2kHiarmUBjCVtXv5qTfVqM3sx8r6GgYYBdoe47d7vM3gI85lIFKNfGXTNS1nfnMJ0O2Vx.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 4 – FDA inspection report (example 3)</em></figcaption></figure>\n<p>‍</p>\n<p>‍<strong>Software released without appropriate change control:</strong></p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319802a7f2bdc92e26e_AD_4nXf5fGQBVbyvPH8X1uQaDUMN6dg4q0LFqdAdqajRE4CfGEchpx3CCe9h0CoWkjfJ4X1IKVoqpOuMd174A6x2RK_jvw1KcpDP34i7vd_zbHpdOgXEX2TU4xPw8TQu-dRS9g9Muph-.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319802a7f2bdc92e26e_AD_4nXf5fGQBVbyvPH8X1uQaDUMN6dg4q0LFqdAdqajRE4CfGEchpx3CCe9h0CoWkjfJ4X1IKVoqpOuMd174A6x2RK_jvw1KcpDP34i7vd_zbHpdOgXEX2TU4xPw8TQu-dRS9g9Muph-.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 5 – FDA inspection report (example 4)</em></figcaption></figure>\n<p>‍<strong>Missing documentation and lack of access control:</strong></p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i1.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319d57aaf27bf3ab849_AD_4nXfcweb0IWHdjXcdV6QShRUjUgesIncIoK0GBOPiz0YEfoQt_9w9Sz4E-GAaJRilCPUd_lCiiZ8jhYkSc3m-Hm6R8hBNtLaJZSNuB0q3e0xQqPyM0KBn79DSvqPiGnhtRcbM69EkfQ.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i1.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1319d57aaf27bf3ab849_AD_4nXfcweb0IWHdjXcdV6QShRUjUgesIncIoK0GBOPiz0YEfoQt_9w9Sz4E-GAaJRilCPUd_lCiiZ8jhYkSc3m-Hm6R8hBNtLaJZSNuB0q3e0xQqPyM0KBn79DSvqPiGnhtRcbM69EkfQ.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 6 – FDA inspection report (example 5)</em></figcaption></figure>\n<p>‍<strong>Lack of access control and data validation, no audit trails:</strong></p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i2.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f692e0cb3df98ca1_AD_4nXcrER19TaxT-aneFQEZBY4gM7_IyHZXcpZeCyhzqNT1Iy0nTM0YpOM3sak1BX2bFTjJotcxIL_TR3RVlwK_zGgKNPslGy7FOQiBL4ATIGKLtCqeUfR3vAvTLT4MbhukqKYlhP0.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i2.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb1318f692e0cb3df98ca1_AD_4nXcrER19TaxT-aneFQEZBY4gM7_IyHZXcpZeCyhzqNT1Iy0nTM0YpOM3sak1BX2bFTjJotcxIL_TR3RVlwK_zGgKNPslGy7FOQiBL4ATIGKLtCqeUfR3vAvTLT4MbhukqKYlhP0.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 7 – FDA inspection report (example 6)</em></figcaption></figure>\n<p>‍<strong>Use of unvalidated software:</strong></p>\n<figure class=\"w-richtext-align-fullwidth w-richtext-figure-type-image\">\n<div><img alt=\"\" data-lazy-src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb13187fdbc66e3fc7c294_AD_4nXe1ErWEF2_ONjE2xsynUqkNC6_I-7U0sG-urdv_gHFenn6hOaTUsmg5QZJdkuTV8cB0F7aDK-RbNN8sie_Ak9Yscwt16OSnSHZhjOgle9wUoQHqQZomdpEDMl2vHHMlaj5wWnHJ.png?w=578&amp;ssl=1\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://www.r-bloggers.com/wp-content/plugins/jetpack/modules/lazy-images/images/1x1.trans.gif\"/><noscript><img alt=\"\" data-recalc-dims=\"1\" decoding=\"async\" src=\"https://i0.wp.com/cdn.prod.website-files.com/654fd3ad88635290d9845b9e/67cb13187fdbc66e3fc7c294_AD_4nXe1ErWEF2_ONjE2xsynUqkNC6_I-7U0sG-urdv_gHFenn6hOaTUsmg5QZJdkuTV8cB0F7aDK-RbNN8sie_Ak9Yscwt16OSnSHZhjOgle9wUoQHqQZomdpEDMl2vHHMlaj5wWnHJ.png?w=578&amp;ssl=1\"/></noscript></div><figcaption><em>Image 8 – FDA inspection report (example 7)</em></figcaption></figure>\n<p>In conclusion, all these examples highlight insufficient GSEP (Good Software Engineering Practices), which likely cost the organizations significant time and money.</p>\n<h2><strong>Appsilon’s Role in GxP Compliance</strong></h2>\n<p>At Appsilon, we help companies navigate the complexities of GxP compliance, ensuring the fast adoption of technology while meeting regulatory requirements and mitigating regulatory risks. We offer comprehensive services, from <strong>GxP compliance audits</strong> to building <strong>compliant Shiny dashboards</strong> in R and Python, running on scalable data platforms and the cloud.</p>\n<p>We specialize in pharma and life sciences and have helped multiple Fortune 500 companies develop high-quality software.<a href=\"https://www.appsilon.com/post/gxp-audit-software\" rel=\"nofollow\" target=\"_blank\"><em>‍</em></a></p>\n<blockquote><p><a href=\"https://www.appsilon.com/post/gxp-audit-software\" rel=\"nofollow\" target=\"_blank\"><em>Learn more about how our GxP Audit Service can help you navigate FDA and EMA submissions</em></a><em>.</em></p></blockquote>\n<p>In conclusion, GxP compliance is challenging, especially in complex industries like pharma. While our <a href=\"https://www.appsilon.com/guides/gxp-compliance\" rel=\"nofollow\" target=\"_blank\">comprehensive guide on navigating GxP compliance</a> is a great place to start, there is no one-size-fits-all solution.</p>\n<blockquote><p><em>If you’re confident in your understanding of quality and compliance, double-check your readiness by downloading our </em><a href=\"https://www.appsilon.com/resources/definition-of-done-checklist-for-pharma-teams\" rel=\"nofollow\" target=\"_blank\"><em>Definition of Done (DoD) Checklist for Pharma Teams</em></a><em>.</em></p></blockquote>\n<p><strong>If you need a reliable partner to ensure the high quality of your software and streamline the FDA and EMA submission process, </strong><a href=\"https://www.appsilon.com/contact-us\" rel=\"nofollow\" target=\"_blank\"><strong>reach out to Appsilon</strong></a><strong>.</strong></p>\n<p>The post appeared first on appsilon.com/blog/.</p>\n<div class=\"jp-relatedposts\" id=\"jp-relatedposts\">\n<h3 class=\"jp-relatedposts-headline\"><em>Related</em></h3>\n</div>\n<!-- Share buttons by mashshare.net - Version: 4.0.47-->\n<div style=\"border: 1px solid; background: none repeat scroll 0 0 #EDEDED; margin: 1px; font-size: 13px;\">\n<div style=\"text-align: center;\">To <strong>leave a comment</strong> for the author, please follow the link and comment on their blog: <strong><a href=\"https://appsilon.com/pharma-fda-rejections/\"> Appsilon | Enterprise R Shiny Dashboards</a></strong>.</div>\n<hr/>\n<a href=\"https://www.r-bloggers.com/\" rel=\"nofollow\">R-bloggers.com</a> offers <strong><a href=\"https://feedburner.google.com/fb/a/mailverify?uri=RBloggers\" rel=\"nofollow\">daily e-mail updates</a></strong> about <a href=\"https://www.r-project.org/\" rel=\"nofollow\" title=\"The R Project for Statistical Computing\">R</a> news and tutorials about <a href=\"https://www.r-bloggers.com/how-to-learn-r-2/\" rel=\"nofollow\" title=\"R tutorials\">learning R</a> and many other topics. <a href=\"https://www.r-users.com/\" rel=\"nofollow\" title=\"Data science jobs\">Click here if you're looking to post or find an R/data-science job</a>.\n\n<hr/>Want to share your content on R-bloggers?<a href=\"https://www.r-bloggers.com/add-your-blog/\" rel=\"nofollow\"> click here</a> if you have a blog, or <a href=\"http://r-posts.com/\" rel=\"nofollow\"> here</a> if you don't.\n</div> </div>\n</article>",
    "main_text": "FDA Compliance in Software Development: Cases Where Poor Software Quality Led to Costly FDA Rejections\nPosted on\nMarch 25, 2025\nby\nPaweł Przytuła\nin\nR bloggers\n| 0 Comments\n[This article was first published on\nAppsilon | Enterprise R Shiny Dashboards\n, and kindly contributed to\nR-bloggers\n].  (You can report issue about the content on this page\nhere\n)\nWant to share your content on R-bloggers?\nclick here\nif you have a blog, or\nhere\nif you don't.\nIf you work in pharma, you know how much time and money go into drug development. The last thing you want is a painful FDA rejection, one that not only costs your company millions but also delays critical treatments for patients who need them.\nRegulatory rejections can happen for many reasons, such as insufficient clinical evidence, manufacturing and quality concerns, incomplete applications or missing data, and general safety issues. However, in recent years,\npoor software quality\nhas become a growing yet often overlooked factor.\nBy “software,” we mean not just applications, but also programming environments, languages, and the tools used to process and govern clinical data. As more pharmaceutical companies explore open-source technologies like R alongside SAS for clinical trial analysis, regulatory bodies are paying closer attention to software quality and compliance.\nWith that in mind,\nGxP compliance in software development\nis critical to making this transition smooth and secure. In this article, we’ll examine cases where software quality issues led to costly FDA rejections—so you can learn what to watch for and how to avoid similar setbacks.\nGxP validation in software development starts with the Definition of Done.\nRead how Appsilon implements it for Fortune 500 companies\n.\nTable of contents\nAre Software Quality Issues a Common Reason for FDA Rejections?\nHow FDA Rejection Can Cost Your Company Three-Quarters of its Valuation – And How to Avoid It\nAppsilon’s Role in GxP Compliance\nAre Software Quality Issues a Common Reason for FDA Rejections?\nThere are many reasons why the FDA might reject your drug submission or request improvements during an inspection.\nWhile issues like insufficient clinical evidence, manufacturing concerns, and missing data are often the most cited reasons, software quality plays a crucial role in ensuring compliance and data integrity.\nFor example, poor data processing or flawed statistical analyses can lead to\ninsufficient clinical evidence\n, where trial results fail to demonstrate efficacy due to errors in data handling. Similarly, compliance issues in\nmanufacturing and quality control\nmay arise if software systems used for tracking and reporting do not meet regulatory expectations.\nThe following reasons are much more common:\nInsufficient clinical evidence:\nLack of sufficient data demonstrating the drug’s efficacy.\nManufacturing and quality concerns:\nNon-compliance with\nCurrent Good Manufacturing Practices\n(CGMP), which ensure consistency and safety in drug production.\nIncomplete applications or missing data:\nGaps in documentation or failure to provide required study results.\nSafety concerns:\nAdverse effects of the drug that outweigh its potential benefits.\nHowever, this doesn’t mean that the FDA doesn’t pay attention to software quality.\nThe FDA and other regulatory bodies closely examine the tools and methodologies used in data analysis, clinical trial reporting, and regulatory submissions.  They also receive the data needed to reproduce the analyses done by the sponsor.\nIf your company uses programming languages like R or Python for these tasks, the FDA may evaluate whether your scripts and validation processes comply with their expectations.\nHow an FDA Rejection Can Cost Your Company Three-Quarters of Its Valuation – And How to Avoid It\nLet’s start with a devastating FDA rejection case that broke one company overnight.\nIn late November 2024,\nApplied Therapeutics (APLT) stock plummeted\nafter the FDA rejected its metabolic disease drug. And when we say “plummeted,” we mean it –\nAPLT lost three-quarters of its valuation almost instantly\n:\nImage 1 – APLT stock price (source:\nYahoo Finance\n)\nThe stock dropped from a closing price of $10.21 on November 26 to $2.03 on November 29, representing\nan 80% decrease\n.\nIt is now February 2025, and judging by the chart, the company has yet to recover – partly due to avoidable deficiencies in its clinical application.\nUnfortunately, this is not the only software-related FDA rejection. Here are a few more cases that highlight the importance of GSEP (Good Software Engineering Practices):\nOutlook Therapeutics collapses as FDA rejects application for eye drug\nFDA rejects Theratechnologies application, with problems ‘largely’ centered on manufacturing\n2023 FDA Warning Letters and Software Validation\nTypes of FDA inspections\nIf you’re part of a highly regulated industry like pharma, you’re probably accustomed to FDA inspections. If not, here are a few reasons why the FDA might conduct an inspection:\nPre-approval inspections:\nConducted before approving a new drug application to verify submitted data, assess manufacturing processes, and confirm compliance.\nRoutine GMP inspections:\nConducted periodically based on risk factors, typically every 2 to 4 years.\nFor-cause inspections:\nTriggered by complaints, adverse events, product recalls, or whistleblower reports.\nFollow-up inspections:\nConducted after a previous inspection identified significant deficiencies.\nBioresearch Monitoring (BIMO) inspections:\nConducted to inspect clinical trials, bioequivalence studies, and laboratory practices.\nPost-market inspections:\nConducted after a product is on the market to ensure ongoing quality and regulatory compliance.\nForeign inspections:\nConducted at overseas facilities that manufacture products for the U.S. market.\nExamples of software-related compliance issues\nNow that you know the types of inspections the FDA can conduct, let’s examine real-world FDA inspection reports that highlight software-related issues. All of these reports are publicly available on the\nFDA\nwebsite.\nCommon FDA concerns related to software include software bugs, missing audit trails, security flaws, lack of backup processes, and poor validation of software systems.\nSoftware bugs found, and the system for data acquisition is not properly validated:\nImage 2 – FDA inspection report (example 1)\n‍\nLack of software security controls, no backups, and missing audit trails:\nImage 3 – FDA inspection report (example 2)\n‍\nNo data validation procedures and no access controls:\nImage 4 – FDA inspection report (example 3)\n‍\n‍\nSoftware released without appropriate change control:\nImage 5 – FDA inspection report (example 4)\n‍\nMissing documentation and lack of access control:\nImage 6 – FDA inspection report (example 5)\n‍\nLack of access control and data validation, no audit trails:\nImage 7 – FDA inspection report (example 6)\n‍\nUse of unvalidated software:\nImage 8 – FDA inspection report (example 7)\nIn conclusion, all these examples highlight insufficient GSEP (Good Software Engineering Practices), which likely cost the organizations significant time and money.\nAppsilon’s Role in GxP Compliance\nAt Appsilon, we help companies navigate the complexities of GxP compliance, ensuring the fast adoption of technology while meeting regulatory requirements and mitigating regulatory risks. We offer comprehensive services, from\nGxP compliance audits\nto building\ncompliant Shiny dashboards\nin R and Python, running on scalable data platforms and the cloud.\nWe specialize in pharma and life sciences and have helped multiple Fortune 500 companies develop high-quality software.\n‍\nLearn more about how our GxP Audit Service can help you navigate FDA and EMA submissions\n.\nIn conclusion, GxP compliance is challenging, especially in complex industries like pharma. While our\ncomprehensive guide on navigating GxP compliance\nis a great place to start, there is no one-size-fits-all solution.\nIf you’re confident in your understanding of quality and compliance, double-check your readiness by downloading our\nDefinition of Done (DoD) Checklist for Pharma Teams\n.\nIf you need a reliable partner to ensure the high quality of your software and streamline the FDA and EMA submission process,\nreach out to Appsilon\n.\nThe post appeared first on appsilon.com/blog/.\nRelated\nTo\nleave a comment\nfor the author, please follow the link and comment on their blog:\nAppsilon | Enterprise R Shiny Dashboards\n.\nR-bloggers.com\noffers\ndaily e-mail updates\nabout\nR\nnews and tutorials about\nlearning R\nand many other topics.\nClick here if you're looking to post or find an R/data-science job\n.\nWant to share your content on R-bloggers?\nclick here\nif you have a blog, or\nhere\nif you don't.",
    "meta_description": "If you work in pharma, you know how much time and money go into drug development. The last thing you want is a painful FDA rejection, one that not only costs your company millions but also delays critical treatments for patients who need them. Regulatory rejections can happen for many reasons, such as insufficient clinical […] The post appeared first on appsilon.com/blog/.",
    "meta_keywords": null,
    "og_description": "If you work in pharma, you know how much time and money go into drug development. The last thing you want is a painful FDA rejection, one that not only costs your company millions but also delays critical treatments for patients who need them. Regulatory rejections can happen for many reasons, such as insufficient clinical […] The post appeared first on appsilon.com/blog/.",
    "og_image": "https://wordpress.appsilon.com/wp-content/uploads/2025/03/67cb14f56eab8476242d0af9_66fc17578edc39e2a907790a_Rounding_4-p-1600.webp",
    "og_title": "FDA Compliance in Software Development: Cases Where Poor Software Quality Led to Costly FDA Rejections | R-bloggers",
    "raw_jsonld_article": null,
    "reading_time_min": 6.7,
    "sitemap_lastmod": null,
    "twitter_description": "If you work in pharma, you know how much time and money go into drug development. The last thing you want is a painful FDA rejection, one that not only costs your company millions but also delays critical treatments for patients who need them. Regulatory rejections can happen for many reasons, such as insufficient clinical […] The post appeared first on appsilon.com/blog/.",
    "twitter_title": "FDA Compliance in Software Development: Cases Where Poor Software Quality Led to Costly FDA Rejections | R-bloggers",
    "url": "https://www.r-bloggers.com/2025/03/fda-compliance-in-software-development-cases-where-poor-software-quality-led-to-costly-fda-rejections/",
    "word_count": 1339
  }
}